{"id":"lenalidomide-control","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Neutropenia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"20-30","effect":"Anemia"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Constipation"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Neuropathy (peripheral)"},{"rate":"5-15","effect":"Thromboembolism"},{"rate":null,"effect":"Teratogenicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenalidomide binds to cereblon (CRBN), a component of an E3 ubiquitin ligase complex, leading to selective degradation of Ikaros and Aiolos proteins. This results in enhanced IL-2 and TNF-α production by T cells, increased NK cell activity, and inhibition of angiogenesis. It also has direct cytotoxic effects on certain tumor cells and modulates the bone marrow microenvironment.","oneSentence":"Lenalidomide is an immunomodulatory agent that enhances T-cell proliferation and NK cell activation while promoting anti-angiogenic and direct anti-tumor effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:21.004Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Myelodysplastic syndromes with deletion 5q"},{"name":"Mantle cell lymphoma"},{"name":"Follicular lymphoma"}]},"trialDetails":[{"nctId":"NCT06182774","phase":"PHASE3","title":"Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2024-04-10","conditions":"Multiple Myeloma","enrollment":570},{"nctId":"NCT06932562","phase":"PHASE3","title":"A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant","status":"RECRUITING","sponsor":"European Myeloma Network B.V.","startDate":"2025-12-23","conditions":"Multiple Myeloma","enrollment":1000},{"nctId":"NCT07477587","phase":"PHASE1","title":"A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-05-27","conditions":"Multiple Myeloma (MM)","enrollment":258},{"nctId":"NCT04404283","phase":"PHASE3","title":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-08-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":238},{"nctId":"NCT05827016","phase":"PHASE3","title":"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-06-22","conditions":"Multiple Myeloma","enrollment":1216},{"nctId":"NCT03984097","phase":"PHASE1","title":"A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2019-07-29","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT02659293","phase":"PHASE3","title":"Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2016-04-26","conditions":"Multiple Myeloma","enrollment":180},{"nctId":"NCT00602641","phase":"PHASE3","title":"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02-29","conditions":"Multiple Myeloma","enrollment":306},{"nctId":"NCT04224493","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","status":"RECRUITING","sponsor":"Epizyme, Inc.","startDate":"2020-06-11","conditions":"Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":612},{"nctId":"NCT06207799","phase":"PHASE2","title":"Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-17","conditions":"Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging","enrollment":40},{"nctId":"NCT07355283","phase":"PHASE3","title":"IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","startDate":"2026-02","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":198},{"nctId":"NCT05722405","phase":"PHASE4","title":"Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-07-01","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT07068165","phase":"PHASE2, PHASE3","title":"A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-07-07","conditions":"IgG4 Related Disease","enrollment":198},{"nctId":"NCT04680052","phase":"PHASE3","title":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-04-15","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma","enrollment":654},{"nctId":"NCT06006117","phase":"PHASE3","title":"Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2023-09-05","conditions":"Marginal Zone Lymphoma","enrollment":260},{"nctId":"NCT07189065","phase":"PHASE2","title":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","startDate":"2025-11-27","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":150},{"nctId":"NCT07025005","phase":"PHASE4","title":"Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-08-30","conditions":"Peripheral Neuropathy, Multiple Myeloma, Neoplasms","enrollment":44},{"nctId":"NCT03118466","phase":"PHASE2","title":"Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-09-25","conditions":"AML","enrollment":41},{"nctId":"NCT05564052","phase":"PHASE2","title":"A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-12-06","conditions":"Lymphoma, Mantle-Cell","enrollment":36},{"nctId":"NCT01650701","phase":"PHASE3","title":"A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2012-02","conditions":"Follicular Lymphoma","enrollment":1030},{"nctId":"NCT06082102","phase":"PHASE3","title":"Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2023-12-19","conditions":"Relapsed/Refractory Marginal Zone Lymphoma","enrollment":324},{"nctId":"NCT03993912","phase":"PHASE3","title":"Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2019-10-17","conditions":"Multiple Myeloma","enrollment":294},{"nctId":"NCT04824092","phase":"PHASE3","title":"Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-05-11","conditions":"Diffuse Large B-cell Lymphoma","enrollment":899},{"nctId":"NCT01659658","phase":"PHASE3","title":"Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2012-12-26","conditions":"Relapsed or Refractory Systemic Light Chain Amyloidosis","enrollment":177},{"nctId":"NCT03376477","phase":"PHASE2","title":"Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-09-23","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT06952478","phase":"PHASE3","title":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma","status":"RECRUITING","sponsor":"Celltrion","startDate":"2025-08-12","conditions":"Refractory or Relapsed Multiple Myeloma","enrollment":486},{"nctId":"NCT06464991","phase":"PHASE3","title":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","status":"RECRUITING","sponsor":"Nanjing IASO Biotechnology Co., Ltd.","startDate":"2024-03-27","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT06918002","phase":"PHASE3","title":"Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients","status":"RECRUITING","sponsor":"Intergroupe Francophone du Myelome","startDate":"2025-07-09","conditions":"Multiple Myeloma, Newly Diagnosed","enrollment":824},{"nctId":"NCT06087653","phase":"PHASE1, PHASE2","title":"Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)","status":"RECRUITING","sponsor":"Starton Therapeutics, Inc","startDate":"2023-10-02","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT01476787","phase":"PHASE3","title":"Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2011-12-29","conditions":"Follicular Lymphoma","enrollment":1030},{"nctId":"NCT06895512","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-04","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":386},{"nctId":"NCT03495960","phase":"PHASE2","title":"Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2019-06-15","conditions":"Primary Central Nervous System Lymphoma","enrollment":72},{"nctId":"NCT04096066","phase":"PHASE3","title":"A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione EMN Italy Onlus","startDate":"2019-07-01","conditions":"Multiple Myeloma, New Diagnosis Tumor","enrollment":84},{"nctId":"NCT06742138","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-01","conditions":"Multiple Myeloma","enrollment":284},{"nctId":"NCT05665140","phase":"PHASE2, PHASE3","title":"Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"University Hopsital Schleswig Holstein Campus Lübeck","startDate":"2023-02-03","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":100},{"nctId":"NCT01093196","phase":"PHASE3","title":"Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2009-10","conditions":"Multiple Myeloma","enrollment":660},{"nctId":"NCT01091831","phase":"PHASE3","title":"Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2009-07","conditions":"Multiple Myeloma","enrollment":389},{"nctId":"NCT03413800","phase":"PHASE2","title":"Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2018-02-12","conditions":"Relapsed Hematologic Malignancy, Multiple Myeloma","enrollment":10},{"nctId":"NCT06522555","phase":"PHASE3","title":"The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-07-29","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":100},{"nctId":"NCT06516978","phase":"PHASE2","title":"A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-10-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":528},{"nctId":"NCT02215980","phase":"PHASE3","title":"STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2014-07","conditions":"Multiple Myeloma","enrollment":210},{"nctId":"NCT00551928","phase":"PHASE3","title":"Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2007-06","conditions":"Multiple Myeloma, Newly Diagnosed Patients","enrollment":402},{"nctId":"NCT03952091","phase":"PHASE3","title":"TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"TJ Biopharma Co., Ltd.","startDate":"2019-03-27","conditions":"Multiple Myeloma in Relapse, Refractory Multiple Myeloma","enrollment":289},{"nctId":"NCT05477797","phase":"NA","title":"Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-02-16","conditions":"Progression Free Survival, Overall Survival, Maintenance","enrollment":420},{"nctId":"NCT06321640","phase":"","title":"Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.","status":"RECRUITING","sponsor":"European Institute of Oncology","startDate":"2022-07-08","conditions":"Breast Cancer, Lung Cancer, Melanoma","enrollment":265},{"nctId":"NCT01995708","phase":"PHASE1","title":"CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-01-31","conditions":"Multiple Myeloma","enrollment":28},{"nctId":"NCT06240520","phase":"PHASE1, PHASE2","title":"Optimizing Reversal of HIV Latency With Combination Therapy","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2024-04","conditions":"Hiv","enrollment":49},{"nctId":"NCT03151811","phase":"PHASE3","title":"A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide","status":"TERMINATED","sponsor":"Oncopeptides AB","startDate":"2017-06-12","conditions":"Multiple Myeloma","enrollment":495},{"nctId":"NCT05598580","phase":"PHASE4","title":"Immunomodulators on HIV-1 Reservoir","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-11-20","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT02285062","phase":"PHASE3","title":"Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-02-17","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":570},{"nctId":"NCT03641456","phase":"PHASE2","title":"VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-09-25","conditions":"Myeloma, Newly Diagnosed, High Risk","enrollment":50},{"nctId":"NCT01264315","phase":"PHASE2","title":"Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2008-09","conditions":"Multiple Myeloma","enrollment":53},{"nctId":"NCT05179733","phase":"PHASE3","title":"The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2022-03-02","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":280},{"nctId":"NCT05802992","phase":"PHASE3","title":"The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2022-03-30","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT04835220","phase":"NA","title":"Trial of Oral Lenalidomide Stewardship Program for Veterans","status":"UNKNOWN","sponsor":"W.G. Bill Hefner Medical Center","startDate":"2021-03-26","conditions":"Medication Compliance","enrollment":40},{"nctId":"NCT00633945","phase":"NA","title":"Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2007-11","conditions":"Cutaneous Lupus Erythematosus (CLE)","enrollment":5},{"nctId":"NCT04481815","phase":"PHASE2","title":"Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-10-01","conditions":"PCNSL","enrollment":240},{"nctId":"NCT05558319","phase":"PHASE3","title":"NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide","status":"NOT_YET_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2022-10","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":480},{"nctId":"NCT03619252","phase":"PHASE4","title":"Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents","status":"COMPLETED","sponsor":"Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology","startDate":"2018-07-01","conditions":"Multiple Myeloma, Pneumococcal Infection, Febrile Neutropenia","enrollment":36},{"nctId":"NCT04150328","phase":"","title":"Lenalidomide Monotherapy in R/R DLBCL","status":"COMPLETED","sponsor":"MorphoSys AG","startDate":"2019-04-12","conditions":"Diffuse Large B Cell Lymphoma","enrollment":490},{"nctId":"NCT01556776","phase":"PHASE3","title":"A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2012-07-20","conditions":"Chronic Lymphocytic Leukemia","enrollment":89},{"nctId":"NCT00774345","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy","status":"COMPLETED","sponsor":"Celgene","startDate":"2009-01-27","conditions":"B-cell Chronic Lymphocytic Leukemia","enrollment":317},{"nctId":"NCT04882163","phase":"PHASE1, PHASE2","title":"Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma","status":"WITHDRAWN","sponsor":"Celgene","startDate":"2021-10-10","conditions":"Lymphoma, B-Cell","enrollment":""},{"nctId":"NCT02431208","phase":"PHASE1","title":"A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-07-22","conditions":"Multiple Myeloma","enrollment":85},{"nctId":"NCT01380106","phase":"PHASE2","title":"Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"Boston VA Research Institute, Inc.","startDate":"2010-08","conditions":"Multiple Myeloma","enrollment":33},{"nctId":"NCT04518982","phase":"PHASE2","title":"Sintilimab and Lenalidomide as a Treatment for CAEBV","status":"UNKNOWN","sponsor":"Zhao Wang","startDate":"2020-08-01","conditions":"CAEBV","enrollment":51},{"nctId":"NCT04361643","phase":"PHASE4","title":"Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial","status":"UNKNOWN","sponsor":"Hospital Universitario Getafe","startDate":"2020-10-27","conditions":"COVID-19","enrollment":120},{"nctId":"NCT01245673","phase":"PHASE2","title":"Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2011-05-10","conditions":"Myeloma","enrollment":28},{"nctId":"NCT01021423","phase":"PHASE3","title":"A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).","status":"TERMINATED","sponsor":"Celgene","startDate":"2010-04-01","conditions":"Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma","enrollment":9},{"nctId":"NCT00057616","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.","status":"COMPLETED","sponsor":"Celgene","startDate":"2002-10-01","conditions":"Melanoma, Neoplasm Metastasis","enrollment":274},{"nctId":"NCT02060656","phase":"PHASE2","title":"Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)","status":"UNKNOWN","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2013-09","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":92},{"nctId":"NCT01373294","phase":"PHASE2","title":"Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2011-11-30","conditions":"Bladder Cancer","enrollment":17},{"nctId":"NCT01029262","phase":"PHASE3","title":"A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q","status":"COMPLETED","sponsor":"Celgene","startDate":"2010-01-26","conditions":"Anemia","enrollment":239},{"nctId":"NCT02928419","phase":"PHASE2","title":"Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q","status":"TERMINATED","sponsor":"Associazione Qol-one","startDate":"2015-05","conditions":"Myelodysplastic Syndromes","enrollment":2},{"nctId":"NCT00056160","phase":"PHASE3","title":"CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2003-01-01","conditions":"Multiple Myeloma","enrollment":353},{"nctId":"NCT00424047","phase":"PHASE3","title":"A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2003-01-01","conditions":"Multiple Myeloma","enrollment":351},{"nctId":"NCT01704781","phase":"PHASE1, PHASE2","title":"Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)","status":"COMPLETED","sponsor":"Bionor Immuno AS","startDate":"2012-09","conditions":"HIV-1 Infection","enrollment":36},{"nctId":"NCT00405756","phase":"PHASE3","title":"A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.","status":"COMPLETED","sponsor":"Celgene Corporation","startDate":"2007-01","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":459},{"nctId":"NCT00446433","phase":"PHASE2","title":"A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease","status":"COMPLETED","sponsor":"Celgene Corporation","startDate":"2002-03","conditions":"Crohn's Disease","enrollment":90},{"nctId":"NCT01621672","phase":"PHASE3","title":"UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2010-04","conditions":"Multiple Myeloma","enrollment":42},{"nctId":"NCT01246557","phase":"PHASE1, PHASE2","title":"Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2009-12","conditions":"Chronic Lymphatic Leukemia","enrollment":20},{"nctId":"NCT00109772","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1","status":"TERMINATED","sponsor":"Celgene Corporation","startDate":"2005-02","conditions":"Complex Regional Pain Syndrome, Type I","enrollment":184},{"nctId":"NCT00179621","phase":"PHASE3","title":"Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality","status":"COMPLETED","sponsor":"Celgene Corporation","startDate":"2005-07","conditions":"Myelodysplastic Syndromes","enrollment":205},{"nctId":"NCT00418665","phase":"PHASE2","title":"A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-12","conditions":"Myelodysplastic Syndromes, Thrombocytopenia","enrollment":39},{"nctId":"NCT00120120","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy","status":"COMPLETED","sponsor":"Celgene Corporation","startDate":"2005-01","conditions":"Radiculopathy","enrollment":181},{"nctId":"NCT00474188","phase":"PHASE2","title":"A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"TERMINATED","sponsor":"Celgene Corporation","startDate":"2007-05","conditions":"Diffuse Large B-cell Lymphoma","enrollment":26},{"nctId":"NCT00055562","phase":"PHASE2, PHASE3","title":"Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma","status":"COMPLETED","sponsor":"Celgene Corporation","startDate":"2003-01","conditions":"Melanoma, Neoplasm Metastasis","enrollment":274}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":402,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Revlimid"],"phase":"phase_3","status":"active","brandName":"Lenalidomide (Control)","genericName":"Lenalidomide (Control)","companyName":"University of Chicago","companyId":"university-of-chicago","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenalidomide is an immunomodulatory agent that enhances T-cell proliferation and NK cell activation while promoting anti-angiogenic and direct anti-tumor effects. Used for Multiple myeloma, Myelodysplastic syndromes with deletion 5q, Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}